A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Switching From an Oral Stable Dose of Selexipag
Phase of Trial: Phase III
Latest Information Update: 11 Feb 2018
At a glance
- Drugs Selexipag (Primary) ; Selexipag (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 18 Dec 2017 Planned End Date changed from 9 Jul 2018 to 13 Aug 2018.
- 18 Dec 2017 Planned primary completion date changed from 9 Jul 2018 to 31 Aug 2018.
- 18 Dec 2017 Status changed from not yet recruiting to recruiting.